Asset profile
IONIS-FB-LRx
RNA / oligonucleotide
Evidence outlook · program status
Discontinued, as a strategic decision by the sponsor
IONIS-FB-LRx is Ionis's ligand-conjugated antisense inhibitor of complement factor B. The planned geographic atrophy (dry AMD) study was withdrawn for a change of business objective; the molecule itself continued, with a completed IgA nephropathy study, so the stop is scoped to the AMD market. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
4 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 4 same-indication; 2 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| IONIS-FB-LRx: this drug | Phase 2 | RNA / oligonucleotide | Complement factor B (CFB) | ||
| Sparsentan (Filspari) | Approved | Small molecule | — | ||
| Povetacicept | Phase 3 | Protein / enzyme therapeutic | — | ||
| JADE101 | Phase 2 | Small molecule | — | ||
| ARO-CFB | Phase 1 | RNA / oligonucleotide | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.